Processes for preparing tetrahydroisoquinolines
US-2016022675-A1 · Jan 28, 2016 · US
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9498476B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9498476-B2 |
| Application number | US-201514841024-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 31, 2015 |
| Priority date | Jun 4, 2008 |
| Publication date | Nov 22, 2016 |
| Grant date | Nov 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating depression in a mammal in need thereof comprising administering to the mammal a therapeutically-effective amount of Form N-1 of 2. The method of claim 1 wherein the mammal is a human.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
- A61K31/501Primary
not condensed and containing further heterocyclic rings · CPC title
having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53}) · CPC title
having six-membered rings with one nitrogen as the only ring hetero atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9498476B2 cover?
- The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystal…
- Who is the assignee on this patent?
- Bristol Myers Squibb Co, Albany Molecular Res Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/501. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).